Leaps

Based on the provided articles, Leaps is not directly mentioned, but the articles discuss Bayer's pharmaceutical division and its strategies for navigating patent expirations and fostering growth. The articles highlight the strong performance of Bayer's pharmaceutical portfolio and the company's efforts to develop new blockbuster drugs. The CEO mentions the strongest portfolio in history. While Leaps isn't explicitly detailed, it is Bayer's investment arm, and therefore plays a role in Bayer's overall innovation strategy. The articles suggest that Bayer is actively seeking to mitigate risks associated with patent cliffs and maintain its competitive edge through internal development and, presumably, external investments via Leaps. The current relevance lies in Bayer's need to sustain growth in its pharmaceutical division amidst patent expirations, making its investment strategies, including those potentially executed through Leaps, crucial for its future success.